These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 19192018)

  • 1. Role of tacrolimus (FK506) 0.1% ointment WW in vitiligo in children and imperatives of combine therapy with Trioxsalen and Silymarin suspension in progressive vitiligo.
    Sehgal VN
    J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1218-9. PubMed ID: 19192018
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of vitiligo with 0.1% tacrolimus ointment.
    Travis LB; Weinberg JM; Silverberg NB
    Arch Dermatol; 2003 May; 139(5):571-4; discussion 573. PubMed ID: 12756092
    [No Abstract]   [Full Text] [Related]  

  • 3. Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment.
    Ahn BK; Kim BD; Lee SJ; Lee SH
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):532-3. PubMed ID: 15761441
    [No Abstract]   [Full Text] [Related]  

  • 4. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases.
    Silverberg NB; Lin P; Travis L; Farley-Li J; Mancini AJ; Wagner AM; Chamlin SL; Paller AS
    J Am Acad Dermatol; 2004 Nov; 51(5):760-6. PubMed ID: 15523355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical tacrolimus for treatment of childhood vitiligo in Asians.
    Kanwar AJ; Dogra S; Parsad D
    Clin Exp Dermatol; 2004 Nov; 29(6):589-92. PubMed ID: 15550128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.
    Lan CC; Chen GS; Chiou MH; Wu CS; Chang CH; Yu HS
    Br J Dermatol; 2005 Sep; 153(3):498-505. PubMed ID: 16120133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
    Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color.
    Silverberg JI; Silverberg NB
    J Drugs Dermatol; 2011 May; 10(5):507-10. PubMed ID: 21533297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study.
    Nordal EJ; Guleng GE; Rönnevig JR
    J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1440-3. PubMed ID: 21466589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series.
    Tanghetti EA
    Cutis; 2003 Feb; 71(2):158-62. PubMed ID: 12635898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical tacrolimus for repigmentation of vitiligo.
    Grimes PE; Soriano T; Dytoc MT
    J Am Acad Dermatol; 2002 Nov; 47(5):789-91. PubMed ID: 12399778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients.
    Fai D; Cassano N; Vena GA
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):916-20. PubMed ID: 17659000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study.
    Hartmann A; Bröcker EB; Hamm H
    Acta Derm Venereol; 2008; 88(5):474-9. PubMed ID: 18779885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of tacrolimus ointment in vitiligo alone or in combination therapy.
    Berti S; Buggiani G; Lotti T
    Skin Therapy Lett; 2009 May; 14(4):5-7. PubMed ID: 19585060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo.
    Ho N; Pope E; Weinstein M; Greenberg S; Webster C; Krafchik BR
    Br J Dermatol; 2011 Sep; 165(3):626-32. PubMed ID: 21457214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo.
    Xu AE; Zhang DM; Wei XD; Huang B; Lu LJ
    Int J Dermatol; 2009 Jan; 48(1):86-90. PubMed ID: 19126059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus.
    Taher ZA; Lauzon G; Maguiness S; Dytoc MT
    Br J Dermatol; 2009 Sep; 161(3):654-9. PubMed ID: 19438859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verruca vulgaris following treatment with tacrolimus ointment.
    Narang T; Pahwa M; Kanwar AJ; Parsad D
    Dermatology; 2006; 213(3):254-5. PubMed ID: 17033184
    [No Abstract]   [Full Text] [Related]  

  • 19. Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipotriol cream.
    Bilaç DB; Ermertcan AT; Sahin MT; Oztürkcan S
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):72-3. PubMed ID: 18355205
    [No Abstract]   [Full Text] [Related]  

  • 20. [4-5-8 trimethylpsoralen in vitiligo. Controlled study of its therapeutic and toxic effect in children].
    Ruíz Maldonado R; Tamayo Sánchez L
    Actas Dermosifiliogr; 1975; 66(9-10):513-26. PubMed ID: 1199825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.